Clinical Pharmacology and Therapeutics
-
Publication Venue For
-
Can Innovation in Regulatory Science Address Health Care Cost Burdens?.
105:809-811.
2019
-
Improving the tools of clinical pharmacology: Goals for 2017 and beyond..
101:22-24.
2017
-
Improving evidence developed from population-level experience with targeted agents..
97:478-487.
2015
-
GSK2374697, a Novel Albumin-Binding Domain Antibody (AlbudAb), Extends Systemic Exposure of Exendin-4: First Study in Humans—PK/PD and Safety.
96:704-712.
2014
-
Career Profile.
96:411-411.
2014
-
Phenotype standardization for statin-induced myotoxicity.
96:470-476.
2014
-
Improving the assessment of heart toxicity for all new drugs through translational regulatory science..
95:501-508.
2014
-
Purine pathway implicated in mechanism of resistance to aspirin therapy: Pharmacometabolomics-informed pharmacogenomics.
94:525-532.
2013
-
The clinical utility index as a practical multiattribute approach to drug development decisions..
86:105-108.
2009
-
Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance..
84:497-505.
2008
-
Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities..
84:506-512.
2008
-
The Reference Image Database to Evaluate Response to therapy in lung cancer (RIDER) project: a resource for the development of change-analysis software..
84:448-456.
2008
-
Corrigendum: Editorial (Clinical Pharmacology Therapeutics (2008) 84, (3-6) DOI: 10.1038/clpt.2008.99).
84:430.
2008
-
Corrigendum: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin (Clinical Pharmacology Therapeutics (2008) 84, (326-331) DOI: 10.1038/clpt.2008.10).
84:430.
2008
-
Erratum: Racial differences in blood pressure response to angiotensin-converting enzyme inhibitors in children: A meta-analysis (Clinical Pharmacology Therapeutics (2008) 84, (315-319)).
84:636-.
2008
-
Should the patent system for new medicines be abolished?.
82:488-490.
2007
-
Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam..
82:410-426.
2007
-
Role of the centers for education and research on therapeutics (CERTs) in pharmacovigilance and proper use of therapeutics..
82:118-121.
2007
-
Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites..
79:461-479.
2006
-
Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam..
78:529-539.
2005
-
Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis..
76:452-466.
2004
-
Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone..
76:250-269.
2004
-
Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships..
74:569-580.
2003
-
Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine..
74:543-554.
2003
-
Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity..
73:199-208.
2003
-
Disposition of nasal, intravenous, and oral methadone in healthy volunteers..
72:536-545.
2002
-
Erratum: Fluvoxamine-theophylline interaction: Gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2 (Clinical Pharmacology and Therapeutics (2001) 70 (415-424)).
72:523.
2002
-
A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans..
70:505-517.
2001
-
Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2..
70:415-424.
2001
-
Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation..
67:275-282.
2000
-
Benzodiazepine use and cognitive function among community-dwelling elderly..
64:684-692.
1998
-
Single-dose disulfiram does not inhibit CYP2A6 activity..
64:39-45.
1998
-
Eptifibatide pharmacokinetics in patients undergoing coronary angioplasty..
63:232-232.
1998
-
Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing.
61:205.
1997
-
Bidirectional interaction of valproate and lamotrigine in healthy subjects..
60:145-156.
1996
-
Inhibition of sulfamethoxazole hydroxylamine formation by fluconazole in human liver microsomes and healthy volunteers..
59:332-340.
1996
-
Population pharmacokinetics (PK) and pharmacodynamics (PD) of integrelin, a platelet aggregation inhibitor.
59:PI84-PI84.
1996
-
Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo..
58:556-566.
1995
-
Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone..
56:86-99.
1994
-
Clinical enflurane metabolism by cytochrome P450 2E1..
55:434-440.
1994
-
Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1..
53:643-650.
1993
-
Pharmacokinetics and biochemical efficacy of pirmagrel, a thromboxane synthase inhibitor, in renal allograft recipients..
52:597-604.
1992
-
Treatment of paroxysmal supraventricular tachycardia with oral diltiazem..
51:562-565.
1992
-
Bidisomide (SC-40230), a new antiarrhythmic agent: initial study of tolerability and pharmacokinetics..
51:371-378.
1992
-
PHARMACOKINETICS (PK) OF L-OFLOXACIN IN HIV-INFECTED PATIENTS.
51:182-182.
1992
-
Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol..
51:18-23.
1992
-
New drug application strategies for supraventricular arrhythmias..
49:481-487.
1991
-
Quality of life among hypertensive patients with a diuretic background who are taking atenolol and enalapril..
48:447-454.
1990
-
Benefits, risks, and costs of prescription drugs: a scientific basis for evaluating policy options..
48:111-119.
1990
-
Transdermal nicotine facilitates smoking cessation..
47:323-330.
1990
-
Lack of effect of cimetidine on acetaminophen disposition in humans..
46:591-597.
1989
-
Comparison between continuous and intermittent infusion regimens of cimetidine in ulcer patients..
46:234-239.
1989
-
Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension..
46:208-218.
1989
-
Erratum: Comparison between continuous and intermittent infusion regimens of cimetidine in ulcer patients (Clin Pharmacol Ther 1989; 46: 234-9).
46:500.
1989
-
Vasodilator monotherapy in the treatment of hypertension: comparative efficacy and safety of pinacidil, a potassium channel opener, and prazosin..
44:78-92.
1988
-
Short-term behavioral effects of beta-adrenergic medications in men with mild hypertension..
43:429-435.
1988
-
Chronic effects of nitrendipine on renal hemodynamics and tubular transport..
43:6-15.
1988
-
Effects of high-dose cancer chemotherapy on the absorption of digoxin in two different formulations..
39:25-28.
1986
-
Transdermal nicotine reduces cigarette craving and nicotine preference..
38:450-456.
1985
-
Tocainide kinetics in congestive heart failure..
34:596-603.
1983
-
Hemodynamic effects of the antiarrhythmic drug pirmenol..
32:235-239.
1982
-
Effects of two nonsteroidal anti-inflammatory drugs, indomethacin and oxaprozin, on the kidney..
28:680-689.
1980
-
Nonemergency use of slow infusions of diazoxide..
18:154-157.
1975
-
CYP2B6 GENOTYPE AFFECTS METHADONE DISPOSITION IN CHILDREN AS DEMONSTRATED BY PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING.
2020
-
CYP2B6 GENOTYPE AFFECTS METHADONE DISPOSITION IN CHILDREN AS DEMONSTRATED BY PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING.
2020
-
EVALUATION OF A PEDIATRIC PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL FOR SOLITHROMYCIN USING PLASMA AND DRIED BLOOD SPOTS (DBS) DRUG CONCENTRATIONS.
2020
-
EVALUATION OF A PEDIATRIC PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODEL FOR SOLITHROMYCIN USING PLASMA AND DRIED BLOOD SPOTS (DBS) DRUG CONCENTRATIONS.
2020
-
EXTERNAL EVALUATION OF POPULATION PHARMACOKINETIC (PPK) MODELS OF TRIMETHOPRIM (TMP) AND SULFAMETHOXAZOLE (SMX) DEVELOPED USING OPPORTUNISTIC DATA IN INFANTS AND CHILDREN.
2020
-
PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING OF MEROPENEM IN PRETERM AND TERM INFANTS.
2020
-
PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING OF MEROPENEM IN PRETERM AND TERM INFANTS.
2020
-
POPULATION PHARMACOKINETICS OF A NOVEL TGF-BETA RECEPTOR I KINASE INHIBITOR VACTOSERTIB IN PATIENTS WITH ADVANCED-STAGE SOLID TUMORS.
2019
-
DOSE-RELATED INFLAMMATORY EFFECTS OF INTRAVENOUS ENDOTOXIN IN HUMANS: EVALUATION OF A NEW CLINICAL LOT (CCRE LOT 94332B1) OF ESCHERICHIA COLIO: 113 ENDOTOXIN (LPS).
2018
-
INTRA-TARGET MICRODOSING (ITM), A NOVEL DRUG DEVELOPMENT APPROACH: PROOF-OF-CONCEPT IN HUMANS
2017
-
LEAN BODY WEIGHT (LBW) DOSING OF PANTOPRAZOLE IS APPROPRIATE FOR OBESE CHILDREN.
2017
-
SUBPHENOTYPES IN MAJOR DEPRESSIVE DISORDER TO BETTER CHARACTERIZE PHARMACOGENOMIC ANTIDEPRESSANT TREATMENT RESPONSE
2017
-
A METFORMIN METABOLOMIC EXPRESSION PROFILE STUDY UTILIZING AN ELECTRONIC HEALTH RECORD (EHR)-LINKED BIOREPOSITORY AND INTEGRATIVE MOLECULAR EPIDEMIOLOGY APPROACHES
2016
-
ANTIFUNGAL EXTRACTION BY THE EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) CIRCUIT EX VIVO.
2015
-
GLYCINE AND A GLYCINE DEHYDROGENASE (GLDC) SNP AS SSRI RESPONSE BIOMARKERS IN DEPRESSION: PHARMACOMETABOLOMICS-INFORMED PHARMACOGENOMICS
2011
-
GLYCINE AND A GLYCINE DEHYDROGENASE (GLDC) SNP AS SSRI RESPONSE BIOMARKERS IN DEPRESSION: PHARMACOMETABOLOMICS-INFORMED PHARMACOGENOMICS
2011
-
DIFFERING SIROLIMUS-INDUCED HYPERLIPIDEMIA AND RESPONSE TO STATIN THERAPY BETWEEN CYP3A5 EXPRESSERS AND NON-EXPRESSERS IN KIDNEY TRANSPLANTATION.
2009
-
USE OF MONTE CARLO SIMULATION (MCS) TO EVALUATE TOXICITY AND EFFICACY BREAKPOINTS OF A NOVEL ANTIBIOTIC
2009